. 2021 Jul 30;11:699301. doi: 10.3389/fonc.2021.699301

Table 2.

Studies in the literature with comparison of PET and visible 5-ALA fluorescence including LGG (WHO grade II).

Publication	Year	Total	Histopathological diagnosis		Positive 5-ALA fluorescence		PET tracer	PET T/N ratio
		n	n		n	(%)		5-ALA pos	5-ALA neg

Stockhammer et al.	2009	13	1	WHO° II	1/1	(100)	FET	2.321	1.142
			1	WHO° III	1/1	(100)		*p<0.0001*
			11	WHO° IV	11/11	(100)		*p<0.0001*

Widhalm et al.	2010	17	8	WHO° II	0/8	(0)	MET	2.3	1.2
			9	WHO° III	8/9	(89)		*p=0.037*

Floeth et al.	2011	30	13	WHO° II	1/13	(8)	FET	n.d.	n.d.
			15	WHO° III	8/15	(53)
			2	WHO° IV	2/2	(100)

Ewelt et al.	2011	30	13	WHO° II	1/13	(8)	FET	2.82	1.33
			15	WHO° III	9/15	(60)		*p=0.026*
			2	WHO° IV	2/2	(100)		*p=0.026*

Arita et al.	2012	11	2	WHO° II	n.d.	n.d.	MET	1.66	1.41
			2	WHO° III				p=0.367
			7	WHO° IV				p=0.367

5-ALA, 5-aminolevulinic acid; FET, O-[2- (18F)fluoroethyl]-L-tyrosine; MET, methionine; n.d., no data; PET, positron emission tomography. T/N ratio, tumor to normal brain ratio; WHO, World Health organization.

Bold = significant.